


## AS1269574

<b>Cat. No.:</b>	HY-107535
<b>CAS No.:</b>	330981-72-1
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>14</sub> BrN <sub>3</sub> O
<b>Molecular Weight:</b>	308.17
<b>Target:</b>	GPR119; TRP Channel
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Membrane Transporter/Ion Channel
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 250 mg/mL (811.24 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	3.2450 mL	16.2248 mL	32.4496 mL
		5 mM	0.6490 mL	3.2450 mL	6.4899 mL
	10 mM	0.3245 mL	1.6225 mL	3.2450 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (6.75 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (6.75 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (6.75 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	AS1269574 is a potent, orally available GPR119 agonist, with an EC <sub>50</sub> of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes <sup>[1][2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	GPR119	TRPA1
<b>In Vivo</b>	AS1269574 significantly reduced the blood glucose AUC after 2 h (AUC <sub>0-2h</sub> ) of administration <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

---

Animal Model:	Eight-week-old ICR mice <sup>[1]</sup>
Dosage:	100 mg/kg
Administration:	P.o.
Result:	Significantly reduced the blood glucose AUC after 2 h (AUC <sub>0-2h</sub> ) of administration. Similarly, plasma insulin AUC <sub>0-2h</sub> was significantly higher in the mice.

---

## REFERENCES

[1]. Yoshida S, et al. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. *Biochem Biophys Res Commun.* 2010;400(3):437-441.

[2]. Chepurny OG, et al. GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion. *Mol Endocrinol.* 2016;30(6):614-629.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA